美国安进药厂公布第二季业绩，营收同比增长9%至91.79亿美元，高于市场预期的89.4亿美元；净利润同比增长92%至14.32亿美元，合每股盈利2.65美元；调整后为每股盈利6.02美元，高于市场预期的5.29美元。期内，产品销售额增长9%，主要由成交量增长推动，并部分被净售价降低3%所抵消。有15种产品实现了至少两位数的销售增长，包括Repatha、Evenity和Imdeltra。 展望全年，安进上调业绩指引，目前预计营收将介于350亿至360亿美元之间(此前预期为343亿至357亿美元)，市场预期为354亿美元；调整后每股收益将介于20.2至21.3美元(此前预期为20至21.2美元)，市场预期为20.91美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.